Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials
In two trials of adults with active thyroid eye disease (n=171), more patients receiving teprotumumab than placebo achieved a proptosis response (77% v 15%, number needed to treat 1.6; primary endpoint), diplopia response (NNT 2.5) and overall response (NNT 1.7) at 24 wks.
Source:
The Lancet Diabetes & Endocrinology
SPS commentary:
Teprotumumab is an insulin-like growth factor-1 receptor inhibiting monoclonal antibody, that was approved in the US in January 2020 on the basis of these two trials. A related Comment notes thyroid eye disease is a heterogeneous condition that often improves spontaneously over time; therefore, more data about the effects of teprotumumab on different thyroid eye disease manifestations at different stages of the disease time-course and comparisons with other immunosuppressive therapies are required to further establish its therapeutic role.